Retina. 2012 Feb;32 Suppl 1:288-98. doi: 10.1097/iae.0b013e31823f99a9.
Most patients with central serous chorioretinopathy (CSC) have spontaneous resolution of exudative macular detachments and a good visual prognosis. Patients with CSC have a primary choroidal hyperpermeability problem evident as multifocal areas of hyperpermeability during indocyanine green (ICG) angiography. A small percentage of patients develop chronic or progressive disease with widespread decompensation of the retinal pigment epithelium and severe vision loss. There is no known treatment for this variant of the disorder.
To study ICG-guided photodynamic therapy (PDT) with verteporfin as a potential treatment for patients with chronic CSC.
Twenty eyes of 15 patients were studied with fluorescein angiography, optical coherence tomography, and ICG angiography to diagnose the maculopathy, monitor the detachments, and localize the choroidal hyperpermeability of the disorder. PDT with ICG guidance was applied to areas of choroidal hyperpermeability, and the patients were observed to determine the anatomic and functional outcomes.
Photodynamic therapy guided by ICG was associated with complete resolution of exudative macular detachments in 12 patients and incomplete resolution in the remaining eight eyes. The vision improved in six eyes and remained unchanged in 14 eyes during a mean follow-up of 6.8 months. Six weeks after treatment, the mean visual acuity improved by 0.55 lines, an amount that was marginally significant. There was a significant inverse correlation between the baseline visual acuity and the amount of improvement in acuity at 6 weeks. No patient had any treatment-related side effects.
Indocyanine green angiography-guided PDT with verteporfin seems to aid in the resolution of exudative detachments in patients with chronic CSC. This treatment was associated with a rapid reduction in subretinal fluid and improvement in visual acuity. Although the follow-up time and number of patients in this pilot study were limited, the encouraging results and lack of complications suggest that further study is indicated.
大多数中心性浆液性脉络膜视网膜病变(CSC)患者的渗出性黄斑脱离可自发缓解,且预后良好。CSC 患者存在原发性脉络膜高通透性问题,在吲哚菁绿(ICG)血管造影中表现为多处高通透性区。一小部分患者出现慢性或进行性疾病,表现为视网膜色素上皮广泛失代偿和严重视力丧失。目前尚无针对这种疾病变异的已知治疗方法。
研究以维替泊芬为代表的 ICG 引导光动力疗法(PDT)治疗慢性 CSC 的效果。
对 15 例(20 只眼)患者进行荧光素血管造影、光学相干断层扫描和 ICG 血管造影检查,以诊断黄斑病变、监测脱离情况并定位病变脉络膜高通透性区。用 ICG 引导 PDT 治疗脉络膜高通透性区,并观察患者的解剖和功能结果。
ICG 引导 PDT 治疗后,12 例患者的渗出性黄斑脱离完全缓解,8 例患者部分缓解。平均随访 6.8 个月期间,6 只眼视力提高,14 只眼视力不变。治疗后 6 周,平均视力提高 0.55 行,有统计学意义。视力基线值与 6 周时视力提高量呈显著负相关。无患者出现与治疗相关的不良反应。
维替泊芬的 ICG 引导 PDT 似乎有助于促进慢性 CSC 患者渗出性脱离的吸收。这种治疗方法可迅速减少视网膜下液并提高视力。尽管本研究的随访时间和患者数量有限,但结果令人鼓舞,且无并发症发生,提示进一步研究是必要的。